It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Epigenetic remodeling is emerging as a critical process for several neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS). Genetics alone fails to explain the etiology of ALS, the investigation of the epigenome might therefore provide novel insights into the molecular mechanisms of the disease. In this study, we interrogated the epigenetic landscape in peripheral blood mononuclear cells (PBMCs) of familial ALS (fALS) patients with either chromosome 9 open reading frame 72 (C9orf72) or superoxide dismutase 1 (SOD1) mutation and aimed to identify key epigenetic footprints of the disease. To this end, we used an integrative approach that combines chromatin immunoprecipitation targeting H3K27me3 (ChIP-Seq) with the matching gene expression data to gain new insights into the likely impact of blood-specific chromatin remodeling on ALS-related molecular mechanisms. We demonstrated that one of the hub molecules that modulates changes in PBMC transcriptome in SOD1-mutant ALS patients is ATF3, which has been previously reported in an SOD1G93A mouse model. We also identified potential suppression of SNAP25, with impaired ATF3 signaling in SOD1-mutant ALS blood. Together, our study shed light on the mechanistic underpinnings of SOD1 mutations in ALS.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 German Center for Neurodegenerative Diseases (DZNE), Ulm, Germany (GRID:grid.424247.3) (ISNI:0000 0004 0438 0426)
2 University Clinic, University of Ulm, Department of Neurology, Ulm, Germany (GRID:grid.6582.9) (ISNI:0000 0004 1936 9748)
3 University Clinic Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg, Institute of Human Genetics, Erlangen, Germany (GRID:grid.5330.5) (ISNI:0000 0001 2107 3311)
4 German Center for Neurodegenerative Diseases (DZNE), Ulm, Germany (GRID:grid.424247.3) (ISNI:0000 0004 0438 0426); University Clinic, University of Ulm, Department of Neurology, Ulm, Germany (GRID:grid.6582.9) (ISNI:0000 0004 1936 9748)